Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Radiotherapy causes dose-limiting toxicity and long-term complications in rapidly renewing tissues, including the gastrointestinal tract. Currently, there is no FDA-approved agent for the prevention or treatment of radiation-induced intestinal injury. In this study, we have shown that PD 0332991 (PD), an FDA-approved selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), prevents radiation-induced lethal intestinal injury in mice. Treating mice with PD or a structurally distinct CDK4/6 inhibitor prior to radiation blocked proliferation and crypt apoptosis and improved crypt regeneration. PD treatment also enhanced LGR5+ stem cell survival and regeneration after radiation. PD was an on-target inhibitor of RB phosphorylation and blocked G1/S transition in the intestinal crypts. PD treatment strongly but reversibly inhibited radiation-induced p53 activation, which blocked p53-upregulated modulator of apoptosis-dependent (PUMA-dependent) apoptosis without affecting p21-dependent suppression of DNA damage accumulation, with a repair bias toward nonhomologous end joining. Further, deletion of PUMA synergized with PD treatment for even greater intestinal radioprotection. Our results demonstrate that the cell cycle critically regulates the DNA damage response and survival of intestinal stem cells and support the concept that pharmacological quiescence is a potentially highly effective and selective strategy for intestinal radioprotection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The DNA Damage Response: Ten Years After
Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705 · cited 2×
“Radiation induces DNA double-strand breaks (DSBs) and rapidly activates the G1/S checkpoint via ATM- and p53-dependent mechanisms in normal cells (18, 19).”
BackgroundCoexistence of Quiescent and Active Adult Stem Cells in Mammals
Li, L., & Clevers, H. (2010) · Science · doi:10.1126/science.1180794 · Cited by 1,247 · cited 1×
“Stem cells are regulated by extracellular cues from the niche (51), while very little is known about how the niche regulates intestinal recovery from injury.”
BackgroundFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“PD suppresses the growth of xenografts via an RB-dependent mechanism (17) and received accelerated FDA approval in 2015 for the treatment of estrogen receptor–positive (ER-positive) and human epidermal growth factor receptor 2– negative (HER2-negative) breast cancer.”
BackgroundHematopoietic Stem Cell Quiescence Promotes Error-Prone DNA Repair and Mutagenesis
Mohrin, M., Bourke, E., Alexander, D., Warr, M. R., Barry-Holson, K., Le Beau, M. M., Morrison, C. G., & Passegué, E. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.06.014 · Cited by 599
Lgr5 stem cells are indispensable for radiation-induced intestinal regeneration
Metcalfe, C., Kljavin, N. M., Ybarra, R., & de Sauvage, F. J. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2013.11.008 · Cited by 575
Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA
Chen, J., Jackson, P. K., Kirschner, M. W., & Dutta, A. (1995) · Nature · doi:10.1038/374386a0 · Cited by 548 · cited 1×
“Interestingly, early studies have demonstrated that distinct domains of p21 bind to CDKs and proliferating cell nuclear antigen (PCNA) to regulate the cell cycle and DNA replication and repair, respectively (39, 40).”
BackgroundMultiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255
Johnson, S. M., Torrice, C. D., Bell, J. F., Monahan, K. B., Jiang, Q., Wang, Y., Ramsey, M. R., Jin, J., Wong, K.-K., Su, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41402 · Cited by 168
Soria, G., Speroni, J., Podhajcer, O. L., Prives, C., & Gottifredi, V. (2008) · Journal of Cell Science · doi:10.1242/jcs.027730 · Cited by 94
Guo, J., Longshore, S., Nair, R., & Warner, B. W. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806133200 · Cited by 64 · cited 1×
“Western blotting revealed a marked inhibition of IR-induced phosphorylation of CHK1, BRCA1, and p53, with on-target inhibition of p-RB (28) in the mucosa of PD-treated mice (Figure 5C).”
Background
Cited by
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Álvarez-Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 390
Vitale, I., Manic, G., De Maria, R., Kroemer, G., & Galluzzi, L. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.04.006 · Cited by 361
Levy, K., Natarajan, S., Wang, J., Chow, S., Eggold, J. T., Loo, P. E., Manjappa, R., Melemenidis, S., Lartey, F. M., Schüler, E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78017-7 · Cited by 276
Metadata
- Authors
- Wei, L., Leibowitz, B. J., Wang, X., Epperly, M., Greenberger, J., Zhang, L., & Yu, J.
- Venue
- Journal of Clinical Investigation
- Published
- 2016-10-04
- Volume
- 126
- Issue
- 11
- Pages
- 4076-4087
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2529293802
- Cited by
- 96
- References
- 10
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.